Stock listing
BOATS:RXST RxSight, Inc. Stock
US listing (BOATS) of RxSight, Inc. · home listing NASDAQ:RXST
Follow RxSight, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:RXST
$4.47 USD -0.54 (-10.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RXST
- Day range
- $4.45 – $4.75 USDNov 20, 2026
- Volume
- 539,306 sharesNov 20, 2026
- Market cap
- $187.4M USDAt the close on Nov 20, 2026 · price × 41.93M shares outstanding
- 52-week range
- $4.11 – $13.22 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.43M USDMedian day 743,694 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RXST · Home | $4.47 USD | -0.54 (-10.8%) | 539,306 | $4.56 | $4.751 | $4.45 | $5.01 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RXST · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.47 | -0.54 | -10.8% | $4.56 | $4.751 | $4.45 | 539,306 | |
| $5.01 | +0.18 | +3.7% | $4.82 | $5.07 | $4.80 | 736,093 | |
| $4.83 | -0.47 | -8.9% | $5.26 | $5.29 | $4.705 | 1,025,747 | |
| $5.30 | -0.02 | -0.4% | $5.31 | $5.43 | $5.18 | 1,002,248 | |
| $5.32 | -0.06 | -1.1% | $5.45 | $5.63 | $5.29 | 534,549 | |
| $5.38 | +0.10 | +1.9% | $5.25 | $5.50 | $5.04 | 963,002 | |
| $5.28 | +0.38 | +7.8% | $4.87 | $5.29 | $4.84 | 808,160 | |
| $4.90 | +0.04 | +0.8% | $4.81 | $5.12 | $4.74 | 1,082,341 | |
| $4.86 | +0.32 | +7.0% | $4.61 | $4.96 | $4.585 | 1,868,627 | |
| $4.54 | 0.00 | 0.0% | $4.55 | $4.60 | $4.36 | 948,254 | |
| $4.54 | -0.45 | -9.0% | $5.05 | $5.135 | $4.40 | 1,494,802 | |
| $4.99 | +0.40 | +8.7% | $4.11 | $5.445 | $4.11 | 2,753,287 | |
| $4.59 | -0.21 | -4.4% | $4.78 | $4.78 | $4.545 | 1,196,930 | |
| $4.80 | -0.07 | -1.4% | $4.91 | $5.01 | $4.79 | 757,418 | |
| $4.87 | -0.18 | -3.6% | $5.06 | $5.065 | $4.845 | 468,434 | |
| $5.05 | +0.15 | +3.1% | $4.97 | $5.19 | $4.92 | 841,601 | |
| $4.90 | 0.00 | 0.0% | $4.76 | $4.94 | $4.75 | 787,843 | |
| $4.90 | -0.03 | -0.6% | $4.97 | $5.045 | $4.87 | 588,689 | |
| $4.93 | -0.09 | -1.8% | $4.97 | $5.095 | $4.889 | 451,460 | |
| $5.02 | -0.06 | -1.2% | $5.07 | $5.105 | $5.01 | 326,804 | |
| $5.08 | +0.18 | +3.7% | $4.89 | $5.09 | $4.84 | 393,229 | |
| $4.90 | +0.02 | +0.4% | $4.87 | $5.04 | $4.77 | 577,115 | |
| $4.88 | +0.19 | +4.1% | $4.71 | $4.92 | $4.65 | 453,924 | |
| $4.69 | +0.18 | +4.0% | $4.46 | $4.77 | $4.45 | 743,694 | |
| $4.51 | -0.16 | -3.4% | $4.70 | $4.83 | $4.495 | 1,041,021 | |
| $4.67 | +0.15 | +3.3% | $4.59 | $4.71 | $4.55 | 611,173 | |
| $4.52 | -0.01 | -0.2% | $4.46 | $4.55 | $4.40 | 826,701 | |
| $4.53 | -0.13 | -2.8% | $4.68 | $4.77 | $4.445 | 694,860 | |
| $4.66 | -0.15 | -3.1% | $4.85 | $4.98 | $4.55 | 834,560 | |
| $4.81 | -0.04 | -0.8% | $4.83 | $4.94 | $4.75 | 522,336 | |
| $4.85 | +0.05 | +1.0% | $4.74 | $4.86 | $4.68 | 938,305 | |
| $4.80 | +0.15 | +3.2% | $4.61 | $4.95 | $4.61 | 842,152 | |
| $4.65 | -0.11 | -2.3% | $4.76 | $4.76 | $4.60 | 623,009 | |
| $4.76 | +0.08 | +1.7% | $4.70 | $4.805 | $4.62 | 483,757 | |
| $4.68 | -0.07 | -1.5% | $4.75 | $4.77 | $4.63 | 616,825 | |
| $4.75 | -0.15 | -3.1% | $4.88 | $4.89 | $4.74 | 508,921 | |
| $4.90 | +0.13 | +2.7% | $4.80 | $4.99 | $4.67 | 705,661 | |
| $4.77 | +0.10 | +2.1% | $4.67 | $4.78 | $4.62 | 810,925 | |
| $4.67 | +0.01 | +0.2% | $4.67 | $4.78 | $4.61 | 1,023,181 | |
| $4.66 | -0.07 | -1.5% | $4.72 | $4.78 | $4.63 | 1,118,853 | |
| $4.73 | -0.12 | -2.5% | $4.85 | $4.91 | $4.67 | 1,219,275 | |
| $4.85 | -0.08 | -1.6% | $4.90 | $4.985 | $4.84 | 593,514 | |
| $4.93 | -0.21 | -4.1% | $5.05 | $5.16 | $4.90 | 849,601 | |
| $5.14 | -0.06 | -1.2% | $5.21 | $5.34 | $5.05 | 627,678 | |
| $5.20 | -0.12 | -2.3% | $5.25 | $5.363 | $5.165 | 1,077,975 | |
| $5.32 | -0.08 | -1.5% | $5.58 | $5.58 | $5.17 | 1,011,866 | |
| $5.40 | -0.22 | -3.9% | $5.56 | $5.58 | $5.31 | 802,962 | |
| $5.62 | -0.485 | -7.9% | $6.05 | $6.05 | $5.60 | 679,268 | |
| $6.105 | +0.085 | +1.4% | $6.02 | $6.21 | $5.955 | 632,159 | |
| $6.02 | +0.06 | +1.0% | $6.00 | $6.025 | $5.78 | 450,645 | |
| $5.96 | -0.37 | -5.8% | $6.26 | $6.325 | $5.89 | 667,392 | |
| $6.33 | -0.12 | -1.9% | $6.41 | $6.655 | $6.265 | 1,206,647 | |
| $6.45 | +0.075 | +1.2% | $6.28 | $6.47 | $6.05 | 734,193 | |
| $6.375 | -0.165 | -2.5% | $6.47 | $6.63 | $6.34 | 561,298 | |
| $6.54 | -0.49 | -7.0% | $7.11 | $7.11 | $6.48 | 605,386 | |
| $7.03 | +0.04 | +0.6% | $6.96 | $7.345 | $6.909 | 778,866 | |
| $6.99 | -0.34 | -4.6% | $7.28 | $7.44 | $6.955 | 988,922 | |
| $7.33 | +0.28 | +4.0% | $7.05 | $7.36 | $7.00 | 1,289,585 | |
| $7.05 | +0.44 | +6.7% | $6.59 | $7.06 | $6.55 | 663,403 | |
| $6.61 | +0.23 | +3.6% | $6.36 | $6.69 | $6.27 | 580,116 | |
| $6.38 | -0.02 | -0.3% | $6.36 | $6.61 | $6.185 | 1,720,603 | |
| $6.40 | +0.14 | +2.2% | $6.23 | $6.41 | $6.14 | 366,354 | |
| $6.26 | +0.01 | +0.2% | $6.26 | $6.55 | $6.184 | 480,561 | |
| $6.25 | +0.16 | +2.6% | $6.10 | $6.31 | $6.00 | 1,544,598 | |
| $6.09 | -0.07 | -1.1% | $6.09 | $6.245 | $5.945 | 663,004 |
- Ticker
- BOATS:RXST
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
RxSight, Inc. to Present at the Piper Sandler Healthcare Conference
Latest earnings call · Nov 3, 2026
RxSight (NASDAQ:RXST) Q3 2026 Earnings Call
Replay and transcript
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 14 slides
Latest news
RxSight, Inc. to Present at the Piper Sandler Healthcare Conference
Nov 19, 2026
Closed $4.47 (-10.8%) on Nov 20, 2026
RxSight, Inc. Reports Third Quarter 2026 Results
Nov 3, 2026
Closed $4.99 (+8.7%) on Nov 4, 2026
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Oct 23, 2026
Closed $5.02 (-1.2%) on Oct 23, 2026
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
Oct 20, 2026
Closed $4.90 (+0.4%) on Oct 21, 2026
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
Oct 19, 2026
Closed $4.69 (+4.0%) on Oct 19, 2026
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
Aug 26, 2026
Closed $6.61 (+3.6%) on Aug 27, 2026
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
Aug 5, 2026
Closed $6.08 (-3.3%) on Aug 6, 2026
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
Jul 15, 2026
Closed $5.57 (+6.1%) on Jul 16, 2026
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
Jul 6, 2026
Closed $5.62 (+0.4%) on Jul 7, 2026
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Jul 6, 2026
Closed $5.62 (+0.4%) on Jul 7, 2026
RxSight, Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 20 in the last 12 months · 95 in all · newest Nov 19, 2026 · oldest 2021
- Calls
- 22 calls with a replay · 22 with a transcript · latest Nov 3, 2026
- Decks
- 4 decks · latest August 2026
Where RxSight, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RXST · Home listing | NASDAQ | United States | USD |
| BOATS:RXST · This page | BOATS | United States | USD |
Valuation
EV/sales −0.5× against a median of 2.3×: the lowest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$56.94M USD
- P/E
- Loss
- EV/sales
- −0.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- 76.1%
- Operating margin
- −50.4%
- Net margin
- −43.8%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.44
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| RxSight, Inc. · NASDAQ:RXST | US$187.4M | −US$56.94M | n/a | −0.5× | n/a | 0.7× | −43.8% | 0.0× | 1.44 |
| Pro-Dex, Inc. · NASDAQ:PDEX | US$203.7M | US$190.7M | 16.9× | 2.4× | n/a | 4.1× | 15.1% | 0.0× | 1.15 |
| AOTI, Inc. · LSE:AOTI | US$201.3M | US$208.6M | n/a | n/a | n/a | 9.6× | n/a | 1.0× | n/a |
| United Orthopedic Corporation · TPEX:4129 | US$196.0M | US$201.9M | 11.7× | 1.1× | 5.2× | 1.7× | 9.1% | 0.2× | n/a |
| Electromed, Inc. · AMEX:ELMD | US$190.4M | US$174.6M | 16.0× | 2.3× | 11.1× | 3.6× | 15.8% | 0.0× | 0.62 |
| Shanghai Heartcare Medical Technology Corp. Ltd. Class H · HKEX:6609 | US$190.2M | US$78.11M | 13.7× | 1.0× | 4.3× | 1.0× | 18.1% | 0.0× | n/a |
| Angel Robotics Co., Ltd. · KRX:455900 | US$188.8M | US$169.5M | n/a | 67.6× | n/a | 8.2× | −266.0% | 0.0× | n/a |
| Value Added Technology Co., Ltd. · KRX:043150 | US$181.9M | US$69.59M | 4.3× | 0.2× | 1.2× | 0.5× | 13.0% | 0.0× | n/a |
| Medeon Biodesign, Inc. · TPEX:6499 | US$178.3M | US$149.1M | n/a | 11.7× | n/a | 4.8× | −159.3% | 0.0× | n/a |
| Anika Therapeutics Inc. · NASDAQ:ANIK | US$177.2M | US$156.8M | n/a | 1.3× | 51.7× | 1.3× | −1.4% | 0.2× | 0.68 |
| Guangdong True Health Medical Technology Development Co. Ltd. Class H · HKEX:2697 | US$169.6M | US$96.20M | n/a | 52.7× | n/a | 2.1× | −740.0% | 0.0× | n/a |
| Median of the others | US$189.5M | US$163.1M | 13.7× | 2.3× | 5.2× | 2.9× | 9.1% | 0.0× | 0.68 |
Forecasts
1 buy · 7 hold · 2 sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.10 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.13 · 3 analysts
- Revenue, year to Dec 2026
- 146.8M · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Aziz Mottiwala | President and Chief Executive Officer |
| Mark Wilterding | Chief Financial Officer |
| Ilya Goldshleger | Chief Operating Officer |
| Jim Schindler | Executive Vice President & General Counsel |
| Oliver Moravcevic | Investor Relations |
| Frank Shields | Executive Vice President, Sales & Commercial Strategy |
| Maureen O’Connell | Executive Vice President, Clinical & Regulatory Affairs |
| Patrick Cullen | Executive Vice President, Quality & Infrastructure Operations |
| Eric Weinberg | Chief Business Development Officer |
| Ron Kurtz | Chief Medical Officer |
| Taryn Conway | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| J. Andy Corley | Chairman |
| Aziz Mottiwala | President and Chief Executive Officer |
| Julie B. Andrews | Director |
| Juliet Tammenoms Bakker | Director |
| Robert J. Palmisano | Director |
| Robert Warner | Director |
| Shweta Singh Maniar | Director |
| Tamara R. Fountain | Director |
| William J. Link | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| RxSight (NASDAQ:RXST) Q3 2026 Earnings Call | Tue, Nov 03, 2026 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q2 2026 Earnings Call | Tue, Jul 07, 2026 · 8:00 AM ET | Replay |
| RxSight (NASDAQ:RXST) Q1 2026 Earnings Call | Wed, May 06, 2026 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q4 2025 Earnings Call | Wed, Feb 25, 2026 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q1 2025 Earnings Call | Wed, May 07, 2025 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q4 2024 Earnings Call | Tue, Feb 25, 2025 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q3 2024 Earnings Call | Sat, Nov 09, 2024 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q2 2024 Earnings Call | Mon, Aug 05, 2024 · 4:30 PM ET | Replay |
All 22 calls
| Call | When | Status |
|---|---|---|
| RxSight (NASDAQ:RXST) Q1 2024 Earnings Call | Mon, May 06, 2024 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q4 2023 Earnings Call | Wed, Feb 28, 2024 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q3 2023 Earnings Call | Thu, Nov 09, 2023 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q2 2023 Earnings Call | Mon, Aug 07, 2023 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q1 2023 Earnings Call | Tue, May 09, 2023 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q4 2022 Earnings Call | Mon, Mar 06, 2023 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q3 2022 Earnings Call | Mon, Nov 07, 2022 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q2 2022 Earnings Call | Mon, Aug 08, 2022 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q1 2022 Earnings Call | Thu, May 05, 2022 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q4 2021 Earnings Call | Tue, Mar 08, 2022 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q3 2021 Earnings Call | Wed, Nov 10, 2021 · 4:30 PM ET | Replay |
| RxSight (NASDAQ:RXST) Q2 2021 Earnings Call | Thu, Sep 09, 2021 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · After close | +8.7% |
| Q2 2026 | Aug 5, 2026 · After close | −3.3% |
| Q1 2026 | May 6, 2026 · After close | −14.4% |
| Q4 2025 | Mar 10, 2026 | −2.4% |
| Q3 2025 | Nov 5, 2025 · After close | +3.2% |
| Q2 2025 | Aug 7, 2025 · After close | −7.7% |
| Q1 2025 | May 7, 2025 · After close | −11.2% |
| Q4 2024 | Feb 25, 2025 | −1.1% |
| Q3 2024 | Nov 7, 2024 · After close | −5.6% |
| Q2 2024 | Aug 5, 2024 · After close | +17.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 · After close | −1.0% |
| Q4 2023 | Feb 28, 2024 · After close | −3.2% |
| Q3 2023 | Nov 9, 2023 · After close | +6.2% |
| Q2 2023 | Aug 7, 2023 · After close | +2.7% |
| Q1 2023 | May 9, 2023 · After close | +9.9% |
| Q4 2022 | Mar 6, 2023 · After close | −2.9% |
| Q3 2022 | Nov 7, 2022 · After close | +6.7% |
| Q2 2022 | Aug 8, 2022 · After close | −2.6% |
| Q1 2022 | May 5, 2022 · After close | +7.0% |
| Q4 2021 | Mar 8, 2022 · After close | +11.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 14 slides | August 2026 |
| Q2 2026 Earnings Presentation | Earnings | 14 slides | Jul 7, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 16 slides | Feb 25, 2026 |
| Investor Presentation (January 2026) | Investor deck | 16 slides | January 2026 |
IPO
Priced at US$16.00 a share on Jul 29, 2021.
- Price
- US$16.00 a share
- Shares offered
- 7,350,000 shares of common stock
- Offering size
- US$117.6 million
- Underwriters' option
- Up to 1,102,500 more shares
- Underwriters
- J.P. Morgan, BofA Securities, SVB Leerink, Wells Fargo Securities, BTIG · In the order on the cover
- Shares delivered
- On or about Aug 3, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 17, 2021 |
| Filed publicly | Jul 9, 2021 |
| Amended twice | Newest Jul 28, 2021 |
| Shares registered with an exchange | Jul 28, 2021 |
| Declared effective by the SEC | Jul 29, 2021 |
| Final prospectus, with the price | Jul 30, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 30, 2021 |
| EFFECT · Notice that a registration is effective | Jul 29, 2021 |
| CERT · Exchange's certificate of listing | Jul 29, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 28, 2021 |
| S-1/A · Registration statement, amended | Jul 28, 2021 |
| CORRESP · Letter to the SEC | Jul 27, 2021 |
| CORRESP · Letter to the SEC | Jul 27, 2021 |
| S-1/A · Registration statement, amended | Jul 26, 2021 |
| CORRESP · Letter to the SEC | Jul 22, 2021 |
| CORRESP · Letter to the SEC | Jul 9, 2021 |
All 16 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Jul 9, 2021 |
| UPLOAD · Letter from the SEC | Jul 6, 2021 |
| DRS/A · Draft registration statement, amended | Jun 24, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jun 23, 2021 |
| UPLOAD · Letter from the SEC | Jun 14, 2021 |
| DRS · Draft registration statement | May 17, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 30, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 134.5M | 139.9M | 89.1M | 49.0M | 22.6M | 14.7M | 2.24M |
| Cost of revenue | 31.5M | 41.0M | 35.3M | 27.7M | 18.1M | 13.0M | 4.06M |
| Gross profit | 103.0M | 98.9M | 53.8M | 21.3M | 4.52M | 1.71M | -1.82M |
| Research and development | 38.5M | 34.4M | 29.1M | 26.0M | 24.5M | 21.9M | 29.6M |
| Selling, general and administrative | 112.7M | 101.4M | 74.8M | 58.7M | 32.8M | 15.2M | 15.2M |
| Operating income | -48.2M | -36.9M | -50.1M | -63.3M | -52.8M | -35.4M | -46.1M |
| Depreciation and amortization | 3.27M | 3.58M | 4.08M | 3.88M | 3.98M | 3.85M | 3.93M |
| EBITDA | -44.9M | -33.3M | -46.0M | -59.4M | -48.8M | -31.6M | -42.1M |
| Interest expense | 19.0K | 21.0K | 3.31M | 4.95M | 3.68M | 510.0K | 26.0K |
| Income before tax | -38.9M | -27.4M | -48.6M | -66.7M | -48.7M | 27.6M | 126.2M |
| Income tax | 66.0K | 50.0K | 20.0K | 9.00K | 8.00K | 57.0K | 24.0K |
| Net income | -38.9M | -27.5M | -48.6M | -66.8M | -48.7M | 27.6M | 126.2M |
| Earnings per share, basic | -0.95 | -0.71 | -1.41 | -2.41 | -3.57 | 0.91 | 6.62 |
| Earnings per share, diluted | -0.95 | -0.71 | -1.41 | -2.41 | -3.57 | 0.15 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 19.9M | 16.7M | 9.69M | 11.8M | 24.4M | 14.0M | 7.96M |
| Short-term investments | 208.2M | 220.5M | 117.5M | 94.0M | 135.0M | 55.0M | 72.7M |
| Receivables | 23.4M | 30.1M | 20.3M | 11.0M | 4.86M | 2.87M | 789.0K |
| Inventory | 31.6M | 22.0M | 17.4M | 14.8M | 8.03M | 8.29M | 7.22M |
| Current assets | 287.5M | 293.8M | 168.4M | 134.6M | 176.3M | 81.5M | 90.2M |
| Property, plant and equipment | 13.1M | 12.4M | 10.8M | 10.1M | 11.2M | 13.3M | 19.3M |
| Total assets | 311.8M | 318.6M | 182.6M | 150.2M | 192.7M | 100.7M | 110.4M |
| Accounts payable | 5.30M | 4.54M | 3.86M | 2.60M | 1.69M | 1.13M | 2.20M |
| Current liabilities | 26.3M | 25.9M | 20.9M | 17.2M | 11.1M | 11.6M | 8.46M |
| Long-term debt | 40.2M | 43.4M | 24.4M | ||||
| Total debt | 11.0M | 12.3M | 0 | 40.2M | 39.8M | 24.4M | 5.52M |
| Total liabilities | 36.1M | 37.3M | 22.2M | 60.3M | 54.5M | 44.9M | 415.0M |
| Shareholders' equity | 275.7M | 281.2M | 160.4M | 89.9M | 138.2M | -430.6M | -304.6M |
| Shares outstanding | 41.2M | 40.4M | 36.1M | 28.3M | 27.4M | 27.4M | 19.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -15.5M | -16.9M | -41.6M | -58.9M | -44.7M | -35.2M | -40.6M |
| Capital spending | -3.83M | -5.44M | -4.81M | -2.39M | -1.94M | -2.54M | -4.09M |
| Free cash flow | -19.3M | -22.4M | -46.4M | -61.2M | -46.6M | -37.7M | -44.7M |
| Cash from investing | 16.9M | -99.3M | -22.1M | 40.0M | -81.9M | 15.6M | -5.87M |
| Cash from financing | 1.86M | 123.3M | 61.5M | 6.33M | 137.3M | 25.2M | 1.33M |
| Dividends paid | -643.0K | ||||||
| Share buybacks | -1.42M | -643.0K | 121.9M | ||||
| Change in cash | 3.24M | 7.05M | -2.19M | -12.6M | 10.7M | 5.63M | -45.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 3, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 2, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| SC TO-I/A | Sep 8, 2026 | Acquisition or disposal | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| SC TO-I/A | Aug 24, 2026 | Acquisition or disposal | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 19, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| SC TO-I | Aug 10, 2026 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 24, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jul 23, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 15, 2026 | Management or board change | SEC |
| 8-K · Current report | Jul 6, 2026 | Results | SEC |
| 8-K · Current report | Jul 6, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2026 | Meeting outcome | SEC |
| SD · Specialized disclosure | May 29, 2026 | ESG report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Mar 19, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Feb 27, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Feb 25, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 25, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 25, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| POSASR | Feb 13, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 3, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 8-K · Current report | Dec 23, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 22, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 19, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 4, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 26, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Aug 15, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 4, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 8, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| SD · Specialized disclosure | May 20, 2025 | ESG report | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| DEF 14A · Proxy statement | Apr 21, 2025 | Meeting notice | SEC |
| ARS/A · Annual report to shareholders, amended | Apr 21, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 8, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 2, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 25, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 25, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 29, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 26, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 26, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 22, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Nov 7, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 31, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 28, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 25, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 22, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 22, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 22, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 11, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 10, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 8, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 4, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 26, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 23, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 23, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 17, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 6, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2024 | Results | SEC |
| 144 · Notice of proposed sale | Aug 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 14, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
This page holds 200 of 476 filings. Open Filings
Cap table
Built by 6ix from RxSight, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 41,929,222
- Fully diluted
- 41,929,222
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 41,929,222 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 41,929,222 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| William J. Link Other companies: Tarsus Pharmaceuticals, Inc. (Director · Since at least Oct 15, 2020); LENSAR, Inc. (Director · Since at least Sep 17, 2020); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 5, 2022 · Past); Glaukos Corporation (Director · Jun 24, 2015 – Jun 3, 2021 · Past); Vivani Medical, Inc. (Director · Nov 18, 2014 – Jun 4, 2019 · Past); Flexion Therapeutics Inc (Director · Sep 10, 2014 – Sep 10, 2014 · Past); Inogen, Inc (Director · Feb 12, 2014 – Feb 20, 2014 · Past); Edwards Lifesciences Corporation (Director · May 15, 2013 – May 8, 2020 · Past) | Director · Since at least Jul 29, 2021 |
| Robert J. Palmisano Other companies: AEON Biopharma, Inc. (Board Member · Since at least Feb 8, 2021); Wright Medical Group N.V (President and CEO, Director · Oct 1, 2015 – Nov 11, 2020 · Past); ev3 Inc (President and CEO, Director · Apr 6, 2008 – Jul 9, 2010 · Past); Advanced Medical Optics Inc (Director · May 22, 2007 – May 29, 2008 · Past); Osteotech Inc (Director · Jun 21, 2006 – Nov 16, 2010 · Past); Intralase Corp (President & CEO, Director · Apr 28, 2006 – Apr 2, 2007 · Past) | Director · Since at least Aug 3, 2021 |
| Bakker Juliet Tammenoms Other companies: CeriBell, Inc. (Director · Since at least Oct 10, 2024); Eargo, Inc. (Director · Oct 15, 2020 – May 17, 2021 · Past); Venus Concept Inc (Director · Nov 7, 2019 – Nov 7, 2019 · Past); Axonics Modulation Technologies Inc (Director · Oct 30, 2018 – Sep 18, 2020 · Past); Corcept Therapeutics Incorporated (Director · Mar 25, 2008 – Jan 21, 2011 · Past) | Director · Since at least Jul 29, 2021 |
| Raymond W. Cohen Other companies: InspireMD Inc. (Director · Since at least Jul 31, 2025); Kestra Medical Technologies, Ltd. (Director · Since at least Mar 6, 2025); Axonics Modulation Technologies Inc (Chief Executive Officer, Director · Oct 30, 2018 – Jan 31, 2021 · Past); BioLife Solutions, Inc. (Director · Jan 13, 2017 – Jul 12, 2021 · Past); Spectrum Pharmaceuticals Inc (Director · Jun 27, 2016 – Jun 20, 2019 · Past) | Director · Since at least Jul 31, 2025 |
| Julie B. Andrews Other companies: Orthofix Medical Inc. (CFO · Since at least Jan 15, 2024); AEON Biopharma, Inc. (Director · Feb 8, 2021 – Feb 8, 2021 · Past); Wright Medical Group N.V (SVP, Global Finance · Oct 1, 2015 – Nov 11, 2020 · Past) | Director · Since at least Aug 3, 2021 |
| Aziz Mottiwala Other companies: Tarsus Pharmaceuticals, Inc. (Chief Commercial Officer · Since at least Oct 15, 2020); Opiant Pharmaceuticals Inc (Chief Commercial Officer · Sep 20, 2019 – Sep 20, 2019 · Past) | President and Chief Executive Officer · Since at least Jul 20, 2026 |
| Shelley Thunen Other companies: LENZ Therapeutics, Inc. (Member · Since at least Mar 21, 2024); AEON Biopharma, Inc. (Director · Since at least Jul 21, 2023) | See remarks · Jul 29, 2021 – Apr 14, 2025 · Past |
| Shweta Singh Maniar Other companies: Orthofix Medical Inc. (Director · Since at least Jan 5, 2023); SeaSpine Holdings Corp (Director · Apr 1, 2021 – Jan 5, 2023 · Past) | Director · Since at least Dec 31, 2021 |
| Bruce Robertson Other companies: Exagen Inc. (Director · Since at least Jun 17, 2021) | Director · Jul 29, 2021 – Aug 3, 2021 · Past |
| Juliet Tammenoms Bakker Other companies: CeriBell, Inc. (Director · Since at least Nov 5, 2026) | Director · Since at least Nov 5, 2026 |
All 29 people
| Person | Seat |
|---|---|
| Robert Warner Other companies: Inari Medical Inc (Director · Mar 1, 2022 – Feb 19, 2025 · Past) | Director · Since at least Aug 3, 2021 |
| Tamara R. Fountain Other companies: Sight Sciences, Inc. (Director · Since at least Jul 15, 2022) | Director · Since at least Jan 19, 2023 |
| Christopher Cox | Director · Jul 29, 2021 – Jul 29, 2021 · Past |
| Daniel Mark Schwartz | Director · Jul 29, 2021 – Aug 3, 2021 · Past |
| Eric Weinberg | Chief Business Development Officer · Since at least Jul 29, 2021 |
| Frank Shields | Executive Vice President, Sales & Commercial Strategy · Since at least Nov 3, 2026 |
| Ilya Goldshleger | Chief Operating Officer · Since at least Jul 29, 2021 |
| J. Andy Corley | Chairman · Since at least Jul 15, 2026 |
| Jesse Anderson Corley | Director · Since at least Jul 29, 2021 |
| Jim Schindler | Executive Vice President & General Counsel · Since at least Nov 4, 2026 |
| Mark Wilterding | Chief Financial Officer · Since at least Jan 11, 2026 |
| Maureen O’Connell | Executive Vice President, Clinical & Regulatory Affairs · Since at least Nov 4, 2026 |
| Oliver Moravcevic | Investor Relations · Since at least Nov 3, 2026 |
| Patrick Cullen | Executive Vice President, Quality & Infrastructure Operations · Since at least Nov 4, 2026 |
| Richard M Wolfen | Director · Jul 29, 2021 – Aug 3, 2021 · Past |
| Ronald M MD Kurtz | Chief Medical Officer · Since at least Jul 29, 2021 |
| Ron Kurtz | Chief Medical Officer · Since at least Jul 15, 2026 |
| Scott Gaines | Chief Customer Officer · Since at least Dec 18, 2025 |
| Taryn Conway | Chief Commercial Officer · Since at least Nov 3, 2026 |
Log in to ask 6ix AI your own questions about RxSight, Inc.